MARKET

TPTX

TPTX

Turning Point Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.95
+1.59
+2.72%
After Hours: 59.50 -0.45 -0.75% 16:58 01/17 EST
OPEN
58.89
PREV CLOSE
58.36
HIGH
60.15
LOW
57.18
VOLUME
301.25K
TURNOVER
--
52 WEEK HIGH
67.54
52 WEEK LOW
24.21
MARKET CAP
1.22B
P/E (TTM)
-35.9240
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TPTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TPTX News

  • Turning Point Therapeutics Announces Program Updates and Milestones for 2020
  • GlobeNewswire.5d ago
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13
  • Turning Point Therapeutics Announces Management Transition
  • GlobeNewswire.01/09 22:00

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About TPTX

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
More

Webull offers Turning Point Therapeutics Inc (TPTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.